Meeting
2016 Gastrointestinal Cancers Symposium
Identification of a high-response patient population to S-1 via predictive enrichment strategy analysis of the S-CUBE phase III trial.
Authors
Masatoshi Kudo
Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan
Masatoshi Kudo , Takuji Okusaka , Shuichi Kaneko , Junji Furuse , Madoka Takeuchi , Xuemin Fang , Yoshito Date , Masahiro Takeuchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Clinical Trial Registration Number
JapicCTI-090920
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 229)
DOI
10.1200/jco.2016.34.4_suppl.229
Abstract #
229
Poster Bd #
B17
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.
First Author: Ghassan K. Abou-Alfa
Poster
2017 Gastrointestinal Cancers Symposium
Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo.
First Author: Jordi Bruix
Poster
2016 ASCO Annual Meeting
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
First Author: Andrew X. Zhu
Poster
2016 Gastrointestinal Cancers Symposium
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
First Author: Andrew X. Zhu